Sign in    |    Register


CAS No.: 545445-44-1      Formula: C20H25N3O3

Weight: 355.43100

Synonyms: 5-morpholin-4-yl-1-[4-(2-oxopiperidin-1-yl)phenyl]-2,3-dihydropyridin-6-one;


Influenza (abbreviated as "influenza") is a respiratory infection caused by influenza virus infection. Influenza viruses are generally divided into three types, namely type A (A), type B (B) and type C (C), and type A is easy to break out, spread and circulate in the population. Currently, the effective chemical drugs against the virus mainly include oseltamivir, zanamivir and Peramivir, which has just been approved for market. The targets of these drugs are mainly neuraminidase against the virus. Peramivir was first developed by BioCryst in the United States, and introduced by Shionogi Pharmaceutical in Japan in January 2010. The drug can be used in patients with severe illness, resistance to Tamiflu and inability to take it orally. On April 5, 2013, the State Food and Drug Administration approved the new anti-influenza drug Peramivir sodium chloride injection. According to the website of the China Food and Drug Administration, Peramivir is a new type of anti-influenza virus drug, and existing clinical trial data Chemicalbook proved its effectiveness against influenza A and B. H7N9 is a subtype of the influenza A virus. Peramivir sodium chloride injection is the first intravenous neuraminidase inhibitor in the country, providing a new treatment option for patients with severe influenza, those who cannot receive neuraminidase inhibitors by inhalation or oral administration, and those who do not respond well to or develop resistance to other neuraminidase inhibitors. According to the State Food and Drug Administration, the national drug evaluation authority conducted a strict review of Peramivir sodium chloride injection in accordance with the new drug evaluation regulations, and adopted early intervention and research, strengthening communication and guidance to speed up the approval process and meet clinical needs on the premise of ensuring drug safety and effectiveness, the administration said. At present, oseltamivir phosphate tablets and zanamivir inhalants are approved as neuraminidase inhibitors. Korea is one of the few countries that have approved the marketing of Peramivir, including the United States, Japan and South Korea. 5 or 6 - dihydro - 3 - (4 - morpholine) - 1 - [4 - (2 - oxygen generation - 1 - piperidine base) phenyl] - 2 (1 h) - one of pyridine ketone for pp shaaban impurities. Apixaban is an oral Chemicalbook selective activation Factor X inhibitor developed by Pfizer in conjunction with Bristol-Myers Squibb.

Basic Information
CAS No.:
Molecular Weight:
Appearance & Character:
Melting Point:
>199°C (dec.)
Boiling Point:
625.0±55.0 °C(Predicted)
Flash Point:
Storage Conditions:
Safety Info
Customs Code: